[1] |
付庆华, 夏冰, 杨洪亮, 等. 初诊伴髓外病变的多发性骨髓瘤患者的临床特征及预后分析[J]. 天津医药, 2020, 48(5):415-420.
|
|
FU Q H, XIA B, YANG H L, et al. Clinical features and prognostic analysis of newly diagnosed multiple myeloma with extramedullary disease[J]. Tianjin Med J, 2020, 48(5):415-420. doi:10.11958/20193032.
|
[2] |
WANG Z, ZHANG S, ZHAO Y, et al. MicroRNA-140-3p alleviates intervertebral disc degeneration via KLF5/N-cadherin/MDM2/Slug axis[J]. RNA Biol, 2021, 18(12):2247-2260. doi:10.1080/15476286.2021.1898176.
|
[3] |
SALIMINEJAD K, KHORRAM KHORSHID H R, SOLEYMANI FARD S, et al. An overview of microRNAs:biology,functions,therapeutics,and analysis methods[J]. J Cell Physiol, 2019, 234(5):5451-5465. doi:10.1002/jcp.27486.
|
[4] |
HUANG G, LIU X, ZHAO X, et al. MiR-9 promotes multiple myeloma progression by regulating TRIM56/NF-κB pathway[J]. Cell Biol Int, 2019, 43(11):1223-1233. doi:10.1002/cbin.11104.
|
[5] |
GOBIN E, BAGWELL K, WAGNER J, et al. A pan-cancer perspective of matrix metalloproteases(MMP)gene expression profile and their diagnostic/prognostic potential[J]. BMC Cancer, 2019, 19(1):581. doi:10.1186/s12885-019-5768-0.
|
[6] |
WANG Z, HE J, BACH D H, et al. Induction of m(6)A methylation in adipocyte exosomal LncRNAs mediates myeloma drug resistance[J]. J Exp Clin Cancer Res, 2022, 41(1):4. doi:10.1186/s13046-021-02209-w.
|
[7] |
WANG J, LIU L. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A[J]. J Ovarian Res, 2021, 14(1):165. doi:10.1186/s13048-021-00919-5.
|
[8] |
中国医师协会血液科医师分会, 中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2022年修订)[J]. 中华内科杂志, 2022, 54(12):1066-1070.
|
|
Hematology Branch of Chinese Medical Doctor Association,Hematology Branch of Chinese Medical Association, Multiple Myeloma Professional Committee of Chinese Medical Doctor Association. Guidelines for the diagnosis and treatment of multiple myeloma in China (revised in 2015)[J]. Chin J Intern Med, 2022, 54(12):1066-1070. doi:10.3760/cma.j.issn.0578-1426.2022.12.020.
|
[9] |
WANG Y, DONG L, WAN F, et al. MiR-9-3p regulates the biological functions and drug resistance of gemcitabine-treated breast cancer cells and affects tumor growth through targeting MTDH[J]. Cell Death Dis, 2021, 12(10):861. doi:10.1038/s41419-021-04145-1.
|
[10] |
刘艺, 席振芳. miR-9-5p通过靶向FOXO1抑制急性淋巴细胞白血病进展[J]. 免疫学杂志, 2023, 39(9):809-820.
|
|
LIU Y, XI Z F. MiR-9-5p inhibits the progression of acute lymphocytic leukemia by targeting FOXO1[J]. Journal of Immunology, 2023, 39(9):809-820. doi:10.13431/j.cnki.immunol.j.20230106.
|
[11] |
CHIRON D, JEGO G, PELLAT-DEUCEUNYNCK C. Toll-like receptors: expression and involvement in multiple myeloma[J]. Leuk Res, 2010, 34(12):1545-1550. doi:10.1016/j.leukres.2010.06.002.
|
[12] |
LUDDI A, MARROCCO C, GOVERNINI L, et al. Expression of matrix metalloproteinases and their inhibitors in endometrium:high levels in endometriotic lesions[J]. Int J Mol Sci, 2020, 21(8):2840. doi:10.3390/ijms21082840.
|
[13] |
WANG J, ZHANG Q, WANG D, et al. Microenvironment-induced TIMP2 loss by cancer-secreted exosomal miR-4443 promotes liver metastasis of breast cancer[J]. J Cell Physiol, 2020, 235(7/8):5722-5735. doi:10.1002/jcp.29507.
|
[14] |
FANG J, JIAO Y H, WEI L M, et al. TIMP2 is associated with prognosis and immune infiltrates of gastric and colon cancer[J]. Int Immunopharmacol, 2022, 110:109008. doi:10.1016/j.intimp.2022.109008.
|
[15] |
LIU W, LI Z, CAI Z, et al. LncRNA-mRNA expression profiles and functional networks in osteoclast differentiation[J]. J Cell Mol Med, 2020, 24(17):9786-9797. doi:10.1111/jcmm.15560.
|
[16] |
SUN H, CHEN X. MiR-106b-5p promotes malignant behaviors of cervical squamous cell carcinoma cells by targeting TIMP2[J]. Reprod Sci, 2022, 29(1):203-211. doi:10.1007/s43032-021-00788-9.
|
[17] |
WU H, LIU C, YANG Q, et al. MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4[J]. Autophagy, 2020, 16(4):683-697. doi:10.1080/15548627.2019.1635380.
|